US · DYAI
Dyadic International, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Jupiter, FL 33477-5094
- Website
- dyadic.com
Price · as of 2024-12-31
$0.79
Market cap 28.19M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $33.91 | +4,192.41% |
| Intrinsic Value(DCF) | $0.58 | -26.58% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $1.85 | $0.10 | $0.25 | $0.38 | |
| 2013 | $1.72 | $67.72 | $1.80 | $0.01 | $0.00 |
| 2014 | $1.15 | $103.06 | $0.00 | $0.00 | $3.10 |
| 2015 | $1.50 | $115.57 | $1.92 | $11.72 | $0.00 |
| 2016 | $1.36 | $64.31 | $1.26 | $1.08 | $0.00 |
| 2017 | $1.45 | $39.55 | $1.38 | $1.36 | $0.00 |
| 2018 | $2.77 | $30.45 | $1.24 | $0.51 | $0.00 |
| 2019 | $5.34 | $27.38 | $1.04 | $0.00 | $0.00 |
| 2020 | $4.95 | $26.61 | $0.63 | $0.00 | $0.00 |
| 2021 | $3.45 | $28.60 | $0.19 | $0.00 | $0.00 |
| 2022 | $1.50 | $31.14 | $0.19 | $0.00 | $0.00 |
| 2023 | $1.38 | $28.25 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.45 | $33.91 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Dyadic International, Inc.'s (DYAI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $33.91
- Current price
- $0.79
- AI upside
- +4,192.41%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.58
-26.58% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DYAI | Dyadic International, Inc… | $0.79 | 28.19M | +4,192% | -27% | — | — | -7.32 | 17.21 | 12.16 | -7.12 | — | 17.21 | 65.82% | -168.82% | -166.19% | -139.16% | 396.74% | -64.01% | 2.05 | -13.79 | 4.01 | 3.88 | 0.27 | -1667.00% | 2058.00% | -4091.00% | -9.35% | -1.62 | 267.25% | 0.00% | 0.00% | 0.00% | -6.49 | -9.64 | 10.96 | -9.43 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| ATHE | Alterity Therapeutics Lim… | $3.44 | 58.29M | +500% | +3% | — | — | -6.79 | 1.95 | 15.18 | -2.87 | — | 1.95 | 97.66% | -267.96% | -223.35% | -43.23% | -905.76% | -37.23% | 0.00 | — | 12.98 | 12.62 | 2.26 | -6346.00% | 3532.00% | -920.00% | -13.87% | -3.24 | -711.67% | 0.00% | 0.00% | 24.86% | -2.88 | -3.67 | 7.73 | 6.97 |
| BCAB | BioAtla, Inc. | $0.25 | 14.5M | — | +725% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| ELUT | Elutia Inc. | $1.15 | 49.11M | +1,914% | -3% | — | — | -1.50 | -1.74 | 3.31 | -2.01 | — | -1.48 | 43.93% | -146.26% | -221.33% | 127.15% | 103.81% | -135.63% | -0.53 | -7.46 | 0.69 | 0.54 | -0.25 | -1014.00% | -150.00% | 545.00% | -28.90% | -0.60 | 67.88% | 0.00% | 0.00% | 1.47% | -2.59 | -3.95 | 3.78 | -11.28 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| RNXT | RenovoRx, Inc. | $0.88 | 32.36M | — | — | — | — | -2.56 | 5.04 | 525.37 | -1.43 | — | 5.04 | 100.00% | -25511.63% | -20497.67% | -1192.69% | 333.89% | -183.93% | 0.06 | — | 4.10 | 3.77 | 0.63 | -2600.00% | — | -1093.00% | -40.45% | -4.78 | 278.10% | 0.00% | 0.00% | 25.24% | -1.43 | -1.72 | 365.46 | -8.52 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
| VERU | Veru Inc. | $2.58 | 41.41M | +876% | — | — | — | -1.60 | 1.99 | — | -0.60 | — | 3.18 | 0.00% | — | — | -89.74% | -202.93% | -50.36% | 0.17 | — | 2.43 | 2.35 | 0.36 | -6179.00% | -10000.00% | 3756.00% | -82.38% | -3.86 | -246.33% | 0.00% | 0.00% | 4.46% | -0.86 | -0.71 | — | -15.28 |
About Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
- CEO
- Mark A. Emalfarb
- Employees
- 6
- Beta
- 1.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.58 ÷ $0.79) − 1 = -26.58% (DCF, example).